ストックスクリーナーアプリを入手
10.17
1.90%
0.19
前日終値:
$9.98
開ける：
$9.98
24時間の取引高:
235.86K
Relative Volume:
1.25
時価総額：
$180.38M
収益：
$1.54M
当期純損益:
$-78.54M
株価収益率:
-1.7012
EPS:
-5.978
ネットキャッシュフロー:
$-64.50M
1週間 パフォーマンス:
+10.06%
1か月 パフォーマンス:
+21.80%
6か月 パフォーマンス:
-21.83%
1年 パフォーマンス:
+95.58%
1日の値動き範囲:
$9.89
$10.50
1週間の範囲:
$8.36
$10.50
52週間の値動き範囲:
$4.64
$20.56
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Company Profile
名前
Corbus Pharmaceuticals Holdings Inc
セクター
電話
617-963-0103
住所
500 RIVER RIDGE DRIVE, NORWOOD, MA
Compare CRBP vs VRTX, REGN, ARGX, ALNY, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CRBP
Corbus Pharmaceuticals Holdings Inc
|
10.17 | 180.38M | 1.54M | -78.54M | -64.50M | -5.978 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-30 | 再開されました | B. Riley Securities | Buy |
| 2025-02-28 | 開始されました | William Blair | Outperform |
| 2024-12-02 | 開始されました | Piper Sandler | Overweight |
| 2024-07-30 | 開始されました | Wedbush | Outperform |
| 2024-07-22 | 再開されました | H.C. Wainwright | Buy |
| 2024-06-26 | 開始されました | B. Riley Securities | Buy |
| 2024-06-03 | 繰り返されました | Oppenheimer | Outperform |
| 2024-05-13 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-03-06 | アップグレード | Jefferies | Hold → Buy |
| 2020-09-08 | ダウングレード | BTIG Research | Buy → Neutral |
| 2020-09-08 | ダウングレード | Jefferies | Buy → Hold |
| 2020-09-08 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-09-08 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2020-07-07 | 開始されました | ROTH Capital | Buy |
| 2020-06-17 | 開始されました | BTIG Research | Buy |
| 2020-03-26 | 開始されました | Nomura | Buy |
| 2019-04-05 | 開始されました | Jefferies | Buy |
| 2019-03-20 | 開始されました | Oppenheimer | Outperform |
| 2019-01-11 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2018-12-26 | 開始されました | H.C. Wainwright | Buy |
| 2018-12-07 | 開始されました | RBC Capital Mkts | Outperform |
| 2018-10-24 | 開始されました | B. Riley FBR | Buy |
| 2018-01-19 | 開始されました | Raymond James | Outperform |
| 2017-12-14 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2017-11-08 | 繰り返されました | Noble Financial | Buy |
| 2017-09-29 | 再開されました | Noble Financial | Buy |
| 2017-03-30 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2016-11-15 | 繰り返されました | JMP Securities | Mkt Outperform |
| 2016-11-11 | 繰り返されました | Noble Financial | Buy |
すべてを表示
Corbus Pharmaceuticals Holdings Inc (CRBP) 最新ニュース
(CRBP) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Corbus Pharmaceuticals (NASDAQ: CRBP) seeks approval to expand equity plan and confirm pay policies - stocktitan.net
Corbus Pharmaceuticals Holdings, Inc. advances next-gen ADC targeting Nectin-4 in aggressive cancers - Traders Union
Mizuho raises Corbus Pharmaceuticals stock price target on updated CRB-701 assumptions - Investing.com Canada
CRBP Stock Price, Quote & Chart | CORBUS PHARMACEUTICALS HOLDI (NASDAQ:CRBP) - ChartMill
CRBP PE Ratio & Valuation, Is CRBP Overvalued - Intellectia AI
CEO Change: What is the cash position of Corbus Pharmaceuticals Holdings Inc2026 Opening Moves & High Accuracy Buy Signal Tips - baoquankhu1.vn
Published on: 2026-03-31 10:02:36 - baoquankhu1.vn
Aug Shorts: Can Corbus Pharmaceuticals Holdings Inc ride the EV waveWeekly Trend Summary & Daily Technical Forecast Reports - baoquankhu1.vn
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
STU:3371 PB Ratio: 1.04 — 73% Below Median - gurufocus.com
Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors - MarketWatch
CRBP SEC FilingsCorbus Pharmaceu 10-K, 10-Q, 8-K Forms - stocktitan.net
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Corbus Pharmaceuticals (NASDAQ: CRBP) files $300M shelf to sell equity, debt - Stock Titan
Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Crosses Above 50-Day Moving AverageTime to Sell? - MarketBeat
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Repeat Insider Selling Not A Positive Indicator - simplywall.st
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings, Inc. to present CRB-913 oral CB1 inverse agonist at BMO Summit - Traders Union
[EFFECT] Corbus Pharmaceuticals Holdings, Inc. SEC Filing - Stock Titan
How (CRBP) Movements Inform Risk Allocation Models - Stock Traders Daily
If You Invested $1,000 in Corbus Pharmaceu (CRBP) - stocktitan.net
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Corbus Pharmaceuticals to Participate in the BMO 2026 Metabolic Health Summit - Sahm
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock rises Monday, still underperforms market - MarketWatch
Prosight Management LP Decreases Stock Position in Corbus Pharmaceuticals Holdings, Inc. $CRBP - MarketBeat
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Dermatomyositis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Octapharma, Argenx, AstraZeneca, Bristol-Myers Squibb Company, Pfizer Inc., Octapharma AG, Corbus Pharma, Holdings - Barchart
Dermatomyositis Market: Strong Pharma Growth Forecast Through - openpr.com
HC Wainwright Issues Negative Forecast for CRBP Earnings - MarketBeat
Trading Systems Reacting to (CRBP) Volatility - Stock Traders Daily
Analysts Offer Insights on Healthcare Companies: Medpace Holdings (MEDP), Revolution Medicines (RVMD) and Corbus Pharmaceuticals (CRBP) - The Globe and Mail
Corbus Pharmaceuticals (NASDAQ: CRBP) files $300M shelf registration - Stock Titan
How Much Upside is Left in Corbus Pharmaceuticals (CRBP)? Wall Street Analysts Think 318.33% - Yahoo Finance
Research Analysts Offer Predictions for CRBP FY2030 Earnings - MarketBeat
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Price Expected to Rise, Oppenheimer Analyst Says - MarketBeat
Oppenheimer Raises Price Target for Corbus Pharmaceuticals (CRBP) to $57 | CRBP Stock News - GuruFocus
Corbus Pharmaceuticals Holdings, Inc. 2024 Annual Report: Pipeline, Intellectual Property, Regulatory Overview, and Business Strategy - Minichart
Corbus Pharmaceuticals (CRBP) Beats Q4 EPS Estimates - GuruFocus
Corbus Pharmaceuticals (NASDAQ: CRBP) details 2025 losses, cash and key trial data - Stock Titan
Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results, Highlights Promising CRB-701 and CRB-913 Clinical Updates and Extends Cash Runway Into 2028 - Minichart
Corbus Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Q4 and annual financial update released, Corbus Pharmaceuticals Holdings, Inc. outlines - Traders Union
Corbus Pharmaceuticals 2025 Financials: Q4 Loss of $20.6M, Beats EstimatesNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Corbus Pharmaceuticals Highlights 2025 Results and Pipeline Progress - TipRanks
Corbus Pharmaceuticals: Fourth Quarter Financial Results Overview - Bitget
Corbus Pharmaceuticals (NASDAQ:CRBP) Releases Quarterly Earnings Results - MarketBeat
Corbus Pharmaceuticals Holdings Inc (CRBP) 財務データ
収益
当期純利益
現金流量
EPS
0.49%
1.47%
大文字化:
|
ボリューム (24 時間):